Skandinaviska Enskilda Banken AB publ Has $31.29 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

Skandinaviska Enskilda Banken AB publ decreased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 13.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 276,096 shares of the medical device company’s stock after selling 43,538 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned 0.07% of DexCom worth $31,291,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Migdal Insurance & Financial Holdings Ltd. bought a new position in DexCom in the second quarter worth $25,000. Sachetta LLC lifted its holdings in shares of DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after acquiring an additional 171 shares during the period. DSM Capital Partners LLC bought a new position in shares of DexCom during the 4th quarter worth about $28,000. Crewe Advisors LLC acquired a new stake in shares of DexCom during the 1st quarter valued at about $29,000. Finally, Riverview Trust Co bought a new stake in DexCom in the first quarter valued at about $32,000. Institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 659 shares of DexCom stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the sale, the executive vice president now owns 66,901 shares in the company, valued at approximately $7,646,115.29. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, EVP Michael Jon Brown sold 659 shares of the firm’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $114.29, for a total value of $75,317.11. Following the transaction, the executive vice president now directly owns 66,901 shares in the company, valued at approximately $7,646,115.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,483 shares of company stock worth $201,708. Company insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. Wells Fargo & Company decreased their price target on DexCom from $145.00 to $80.00 and set an “overweight” rating on the stock in a research note on Friday, July 26th. Barclays dropped their price objective on DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research note on Monday, July 29th. Robert W. Baird boosted their target price on shares of DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, August 5th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $145.00 target price on shares of DexCom in a research report on Tuesday, July 23rd. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average target price of $112.25.

DexCom Stock Performance

DXCM stock opened at $70.43 on Friday. The company has a 50 day moving average price of $78.19 and a 200 day moving average price of $109.63. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The stock has a market capitalization of $28.01 billion, a PE ratio of 45.44, a price-to-earnings-growth ratio of 2.12 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The firm’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.34 earnings per share. Analysts forecast that DexCom, Inc. will post 1.69 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.